Regeneron Pharmaceuticals announced new analyses of EYLEA HD Injection 8 mg and EYLEA Injection 2 mg will be presented at the Annual Meeting of the European Society of Retina Specialists, EURETINA, in Barcelona from September 19 to 22, 2024. “The presentations at EURETINA reinforce the efficacy and safety profile of EYLEA HD and the ability to extend dosing intervals leading to significant and positive impacts on patients with wet age-related macular degeneration and diabetic macular edema,” said Boaz Hirshberg, MD, Senior Vice President, Clinical Development, Internal Medicine at Regeneron. “EYLEA HD continues on its way to becoming the new standard of care for these retinal diseases based on its differentiated clinical profile, and its strong familiarity and satisfaction among retinal specialists.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron and Sanofi report Dupixent trial met primary, key secondary endpoints
- Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
- Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
- Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
- Regeneron says Libtayo demonstrates durable survival benefit at five years